![](/img/cover-not-exists.png)
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
Conconi, A., Martinelli, G., Lopez-Guillermo, A., Zinzani, P. L., Ferreri, A. J. M., Rigacci, L., Devizzi, L., Vitolo, U., Luminari, S., Cavalli, F., Zucca, E.Volume:
22
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdq416
Date:
March, 2011
File:
PDF, 177 KB
english, 2011